This study aimed to evaluate the diagnostic efficacy of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early-stage hepatitis virus B (HBV) related hepatocellular carcinoma (HCC). The study compared serum levels of PIVKA-II and a-Fetoprotein (AFP) in 113 patients with clinical confirmed Barcelona Clinic Liver Cancer (BCLC) stage 0-A HBV-related HCC and 161 chronic hepatitis B (CHB) patients.
Diagnostic values of PIVKA-II and AFP in HCC CHB patients are displayed via AUROC of PIVKA-II, AFP and PIVKA-II + AFP.
The results showed that serum PIVKA-II level is a potential marker for early diagnosis of HCC and microvascular invasion. The use of PIVKA-II may improve assessment of tumor prognosis and guide development of therapeutic strategy.